<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710745</url>
  </required_header>
  <id_info>
    <org_study_id>0012020</org_study_id>
    <nct_id>NCT04710745</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation in Relationship to Plasma Biomarkers</brief_title>
  <acronym>AFISBIO II</acronym>
  <official_title>Atrial Fibrillation in Relationship to Plasma Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Premedix Academy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Premedix Academy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of this study is to:&#xD;
&#xD;
      A. To identify novel plasmatic biomarkers associated with prevalent/incident atrial&#xD;
      fibrillation in patients with high risk for AF and stroke.&#xD;
&#xD;
      B. To assess predictive ability of novel plasmatic biomarkers (especially apelin and miRNAs)&#xD;
      on prevalent/incident atrial fibrillation in patients with high risk for AF and stroke.&#xD;
&#xD;
      C. To validate predictive models from previous studies based on comorbidities, age, sex, BMI,&#xD;
      NT-proBNP, FGF-23, IGF-1 and IGFBP-1 on prevalent/incident AF in patients with high risk for&#xD;
      AF and stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common sustained arrhythmia, associated with an&#xD;
      increased risk of stroke, heart failure, and mortality. Despite the high prevalence, AF may&#xD;
      be asymptomatic and consequently unrecognized. Detection of asymptomatic AF is challenging as&#xD;
      only a minority of the patients is diagnosed during standard examinations with a 12 - lead&#xD;
      ECG or a 24h ECG Holter monitoring. Furthermore, prolonged ECG monitoring is costly and can&#xD;
      be inconvenient for the patients. Documented AF causes 15% of ischemic strokes. However,&#xD;
      approximately 25% of ischemic strokes is of an unknown etiology. It is believed that&#xD;
      undetected asymptomatic AF is responsible for some of these strokes.&#xD;
&#xD;
      Plasmatic biomarkers might be of importance in the early diagnosis of AF. Several plasmatic&#xD;
      biomarkers have been studied in order to find an association with AF. Cardiac biomarkers such&#xD;
      as natriuretic peptides and high-sensitivity troponins are increased in patients with AF. A&#xD;
      novel biomarker that is depending on left atrial stretching and ionotropic effects is apelin.&#xD;
      In our previous research we discovered that apelin is associated with AF, negatively&#xD;
      correlates with AF burden, but only in patients without reduced LVEF. Similarly, parameters&#xD;
      reflecting thrombogenesis, such as Fibrinogen and fibrin D-dimer were also found to be&#xD;
      associated with the arrhythmia. Other protein biomarkers have been studied in relation to AF&#xD;
      incidence. Insulin-like growth factor-binding protein 1 (IGFBP-1) and Insulin-like growth&#xD;
      factor 1 (IGF-1) have shown an association with higher risk of incident AF. Previous research&#xD;
      also indicated Fibroblast growth factor 23 (FGF-23) to be associated with AF.&#xD;
&#xD;
      However, biomarkers, such as the inflammatory markers high-sensitivity CRP have shown&#xD;
      conflicting results.&#xD;
&#xD;
      Finally, in the last years, circulating microRNAs emerged as a promising biomarker of AF,&#xD;
      having important function in suppression of messenger RNA responsible for electric and&#xD;
      structural remodeling of the left atria.&#xD;
&#xD;
      In our previous case-matched study we discovered that selected miRNAs were associated with&#xD;
      paroxysmal AF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of AF</measure>
    <time_frame>Within 14 days from Inclusion.</time_frame>
    <description>AF duration &gt; 30s on surface ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AF</measure>
    <time_frame>Within 14 days from Inclusion.</time_frame>
    <description>AF duration &gt; 30s on surface ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular (CV) death</measure>
    <time_frame>Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Event occurred or did not occur (Yes/No).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Event occurred or did not occur (Yes/No).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV death + nonfatal stroke + nonfatal myocardial infarction</measure>
    <time_frame>Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Event occurred or did not occur (Yes/No).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Event occurred or did not occur (Yes/No).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive decline assessed by Mini-Mental State Examination</measure>
    <time_frame>Day 350-380 from inclusion (Follow-up 4) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Impairment observed and recorded or not observed and not recorded (Yes/No).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
    <time_frame>Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Event occurred or did not occur (Yes/No). If Yes, HF classification to be indicated based on LVEF:&#xD;
i. with preserved LVEF (HFpEF) ii. with mid-range LVEF (HFmrEF) iii. with reduced LVEF (HFrEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to CV cause</measure>
    <time_frame>Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Event occurred or did not occur (Yes/No).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndrome</measure>
    <time_frame>Day 175-205 from inclusion (Follow-up 3) - Day 1080-1110 from inclusion (Follow-up 6)</time_frame>
    <description>Event occurred or did not occur (Yes/No). If Yes, type of ACS to be indicated:&#xD;
i. Unstable angina ii. NSTEMI iii. STEMI</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Patients in sinus rhythm without history of AF, with high risk for ischemic stroke and AF. CHA2DS2-VASc score &gt; 2 (for females &gt; 3) and with more than 3 specific criteria for inclusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Peripheral blood samples for routine analysis including NT-proBNP and plasmatic biomarkers.</intervention_name>
    <description>Sampling of peripheral venous blood for analysis of plasma concentration of plasmatic markers (Apelin, microRNA, FGF-23, IGF-1, IGFBP-1) and routine analysis (laboratory parameters: NT-proBNP, D-dimer, Creatinine Clearance, CRP, Hs-troponin).</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>ECHO parameters:&#xD;
E/eÂ´&#xD;
Mean e' septal and lateral wall&#xD;
LA volume (Biplane Area-Length Method)&#xD;
Left atrial volume index&#xD;
Diameter of left atrium in PLAX&#xD;
Severe aortic stenosis&#xD;
Severe mitral regurgitation&#xD;
Severe tricuspid regurgitation&#xD;
Left ventricular end-diastolic diameter&#xD;
Interventricular septum&#xD;
Posterior wall&#xD;
LV Mass&#xD;
Left ventricular mass index</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG Holter monitor</intervention_name>
    <description>Patient receives an ECG Holter for a 7-day monitoring.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standardized Mini-Mental Status Exam (SMMSE)</intervention_name>
    <description>A screening test for evaluating cognitive performance of patients done in the clinician's office.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from Slovak hospitals and outpatient clinics in sinus rhythm without history of&#xD;
        AF, with high risk for ischemic stroke and AF. CHA2DS2-VASc score &gt; 2 (for females &gt; 3) and&#xD;
        with more than 3 specific criteria for inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General inclusion criteria:&#xD;
&#xD;
          -  AGE &gt; 50 years&#xD;
&#xD;
          -  No history of supraventricular arrhythmia&#xD;
&#xD;
          -  Sinus rhythm at inclusion&#xD;
&#xD;
          -  CHADSVASc score &gt; 2 in men (&gt; 3 in female)&#xD;
&#xD;
          -  More than 3 specific criteria for inclusion&#xD;
&#xD;
          -  Written informed consent is obtained before any study-related assessment is performed&#xD;
&#xD;
        Specific inclusion criteria:&#xD;
&#xD;
          -  Age &gt; 65&#xD;
&#xD;
          -  Age &gt; 75&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Heart failure with preserved LVEF (according to ESC GL for HF)&#xD;
&#xD;
          -  Ischemic stroke&#xD;
&#xD;
          -  Left atrial diameter &gt; 45mm&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Arterial hypertension&#xD;
&#xD;
          -  PR interval &gt; 200ms&#xD;
&#xD;
          -  History of MI or (objective evidence of) chronic coronary syndrome&#xD;
&#xD;
          -  Peripheral artery disease&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any supraventricular or ventricular arrhythmia (excluding premature&#xD;
             contractions and 1st degree AV block)&#xD;
&#xD;
          -  Therapy with anticoagulants at the time of inclusion&#xD;
&#xD;
          -  Acute coronary syndrome less than 1 month prior to inclusion&#xD;
&#xD;
          -  History of cardiac surgery&#xD;
&#xD;
          -  Diabetes mellitus type 2&#xD;
&#xD;
          -  Reduced LVEF (&lt;50%)&#xD;
&#xD;
          -  Acute or decompensated heart failure at the time of inclusion&#xD;
&#xD;
          -  Cardiomyopathy&#xD;
&#xD;
          -  Systemic inflammatory disease or acute inflammatory disease&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Alcoholism (â¥ 8 drinks/week)&#xD;
&#xD;
          -  Renal Disease (Dialysis/ transplant/ CrCl &lt; 1ml/s)&#xD;
&#xD;
          -  Liver disease (cirrhosis/ transaminase &gt; 3x ULT/ bilirubin &gt; 2x ULT)&#xD;
&#xD;
          -  Severe or moderate mitral stenosis&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allan BÃ¶hm, MD, PhD, MBA, FESC</last_name>
    <phone>+421 907 411 499</phone>
    <email>allan.bohm@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bratislava - Old Town Hospital</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Äaprnda, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Äaprnda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bratislava - Hospital Ruzinov</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JÃ¡n PÃ¡leÅ¡, MD</last_name>
    </contact>
    <investigator>
      <last_name>JÃ¡n PÃ¡leÅ¡, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bratislava - Hospital of the Academician Ladislav DÃ©rer</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tereza HlavatÃ¡, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tereza HlavatÃ¡, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute for Cardiovascular Diseases</name>
      <address>
        <city>Bratislava</city>
        <zip>833 48</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan BÃ¶hm, PhD, MBA, FESC</last_name>
      <phone>+421 907 411 499</phone>
      <email>allan.bohm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Allan BÃ¶hm, PhD, MBA, FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Malacky</name>
      <address>
        <city>Malacky</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TomÃ¡Å¡ Uher, MD</last_name>
    </contact>
    <investigator>
      <last_name>TomÃ¡Å¡ Uher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Nitra</name>
      <address>
        <city>Nitra</city>
        <zip>950 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Snopek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Snopek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Radovan HurÄÃ­k, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Plasmatic Biomarkers</keyword>
  <keyword>ECG Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

